SS-31 - Research Grade Peptide

SS-31 – Research-Grade Modified Tetrapeptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade, sequence-defined modified tetrapeptide with batch documentation available where supplied
• Defined D-Arg-Dmt-Lys-Phe-NH₂ peptide structure
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, peptide content, molecular form and counter-ion information stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

SS-31, also known as elamipretide, is a sequence-defined modified tetrapeptide comprising D-arginine, 2,6-dimethyl-L-tyrosine, L-lysine and C-terminally amidated L-phenylalanine. Each vial contains measured laboratory material prepared to support controlled scientific handling, storage, analytical method development and peptide characterisation. The stated nominal amount refers to the declared SS-31 peptide content of a single vial, subject to the applicable batch documentation and stated assay basis.

Where dissolution or reconstitution is required, the solvent, buffer, concentration, mixing procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. A universal solvent instruction should not be applied to every SS-31 molecular form or formulation. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: SS-31
• Preferred Substance Name: Elamipretide
• Alternative Designations: SS31; MTP-131; MTP131; RX-31; Bendavia; Szeto-Schiller peptide
• Material Classification: Synthetic sequence-defined modified tetrapeptide
• Sequence Length: Four amino-acid and modified amino-acid residues
• Complete Peptide Sequence: H-D-Arg-2,6-dimethyl-L-Tyr-L-Lys-L-Phe-NH₂
• Structural Shorthand: H-D-Arg-Dmt-Lys-Phe-NH₂
• Dmt Residue: Dmt denotes 2,6-dimethyl-L-tyrosine
• Sequence-Based Chemical Name: D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
• Stereochemical Configuration: All amino-acid residues have the L configuration except for the N-terminal arginine, which has the D configuration
• N-Terminal Structure: Free D-arginine amino terminus
• C-Terminal Structure: C-terminal L-phenylalaninamide
• Cyclic or Linear Structure: Linear peptide
• Cysteine Content: None
• Disulphide-Bond Content: None; the SS-31 sequence contains no cysteine residues
• Parent Elamipretide CAS Number: 736992-21-5
• Parent Elamipretide PubChem Compound Identifier: CID 11764719
• Parent Elamipretide Unique Ingredient Identifier: 87GWG91S09
• Parent Elamipretide Molecular Formula: C₃₂H₄₉N₉O₅
• Parent Elamipretide Average Molecular Weight: Approximately 639.80 g/mol
• Parent Elamipretide InChIKey: SFVLTCAESLKEHH-WKAQUBQDSA-N
• Parent-Formula Basis: The formula C₃₂H₄₉N₉O₅ and molecular weight of approximately 639.80 g/mol describe the parent elamipretide molecular structure without additional hydrochloride, acetate, trifluoroacetate, residual water, solvents or formulation excipients
• Elamipretide Hydrochloride CAS Number: 2244098-12-0
• Elamipretide Hydrochloride Unique Ingredient Identifier: E40WZ3BK2D
• Elamipretide Hydrochloride Salt Form: Elamipretide trihydrochloride, with a peptide-to-hydrochloride relationship of 1:3
• Elamipretide Hydrochloride Formula: C₃₂H₄₉N₉O₅·3HCl
• Expanded Elamipretide Hydrochloride Formula: C₃₂H₅₂Cl₃N₉O₅
• Elamipretide Hydrochloride Average Molecular Weight: Approximately 749.2 g/mol
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied material is parent elamipretide, elamipretide trihydrochloride, an acetate-containing form, a trifluoroacetate-containing form or another counter-ion presentation
• CAS Number Selection: CAS number 736992-21-5 should be used for the parent elamipretide identity, while CAS number 2244098-12-0 applies to the defined elamipretide trihydrochloride
• Molecular-Weight Selection: The molecular weight displayed on the product page, Certificate of Analysis and Safety Data Sheet must correspond to the actual molecular or salt form supplied
• Nominal Amount Basis: The applicable product specification should state whether the declared vial quantity is expressed as parent SS-31 peptide equivalent, total hydrochloride salt material, another counter-ion form or total formulated lyophilised material
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion should be stated in the batch Certificate of Analysis
• Purity Interpretation: Chromatographic purity represents the relative chromatographic composition measured under the stated analytical conditions and should not automatically be interpreted as equivalent to total net SS-31 peptide content
• Peptide-Content Specification: Net SS-31 peptide content should be distinguished from chromatographic purity and interpreted alongside counter-ion content, water content, residual solvents and formulation components
• Sequence Confirmation: The complete D-Arg-Dmt-Lys-Phe-NH₂ sequence should be confirmed using the applicable supplier, synthesis and batch records
• Stereochemical Confirmation: The D-arginine configuration and L configuration of the remaining chiral residues should be supported by appropriate synthesis records or stereochemical analytical documentation
• Modified-Residue Confirmation: Molecular-identity records should confirm the presence of the 2,6-dimethyl-L-tyrosine residue
• C-Terminal Amidation Confirmation: Molecular-identity documentation should confirm the C-terminal phenylalaninamide and distinguish it from a free carboxylic acid terminal structure
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the exact SS-31 molecular or salt form stated for the applicable batch
• Counter-Ion Specification: Hydrochloride, acetate, trifluoroacetate or another counter-ion may affect the total supplied material mass, formula weight and calculated net peptide content
• Water-Content Specification: Residual water and hydration state may contribute to the total material mass and should be stated or controlled through the applicable batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage, purification, salt conversion, concentration and lyophilisation should be stated or controlled through the batch specification
• Related-Impurity Control: Deletion sequences, truncated peptides, incompletely deprotected material, stereochemical impurities, modified-residue impurities and other synthesis-related or process-related substances are separate quality attributes
• Dissolution Method: The appropriate solvent, buffer, concentration and mixing procedure should be selected using the applicable batch documentation and validated laboratory method; a universal bacteriostatic-water instruction should not be applied to every SS-31 chemical form
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Sterility Distinction: A bacterial endotoxin or lipopolysaccharide result does not establish sterility. Sterility should only be claimed where supported by an appropriate validated sterility test and controlled filling process
• Analytical Interpretation: Molecular identity, amino-acid sequence, stereochemistry, terminal amidation, chromatographic purity, net peptide content, salt form, counter-ion content, water content, residual solvents and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete D-Arg-Dmt-Lys-Phe-NH₂ sequence should be confirmed using the applicable synthesis and batch records.
✓ Stereochemical documentation – The D-arginine residue and remaining L-configured residues should be supported by appropriate synthesis or analytical documentation.
✓ Modified-residue documentation – The 2,6-dimethyl-L-tyrosine residue should be confirmed using suitable molecular-identity records.
✓ Terminal-modification documentation – C-terminal phenylalaninamide should be confirmed and distinguished from a free carboxylic acid terminal structure.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified SS-31 molecular or salt form.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net SS-31 peptide content should be distinguished from chromatographic purity and interpreted alongside counter-ion, water and residual-solvent results.
✓ Chemical-form documentation – Parent elamipretide, trihydrochloride, acetate-containing, trifluoroacetate-containing or another counter-ion form should be identified clearly in the applicable product and batch records.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, purification, salt-form and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

SS-31 Product Overview

Our SS-31 research-grade modified tetrapeptide, also known as elamipretide or MTP-131, is supplied for controlled scientific laboratory investigation, analytical method development, modified peptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows and reference-material comparison.

SS-31 comprises a defined four-residue structure containing N-terminal D-arginine, 2,6-dimethyl-L-tyrosine, L-lysine and C-terminally amidated L-phenylalanine. The modified tyrosine residue, D-arginine stereochemistry and terminal phenylalaninamide form part of the molecular identity and should be confirmed through the applicable synthesis records and analytical documentation.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, amino-acid sequence, stereochemical configuration, modified-residue identity, terminal amidation, chromatographic purity, net peptide content, molecular form, counter-ion content, water content, residual solvents, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

The CAS number 736992-21-5, molecular formula C₃₂H₄₉N₉O₅ and average molecular weight of approximately 639.80 g/mol describe the parent elamipretide peptide. Elamipretide trihydrochloride is a separate salt form with CAS number 2244098-12-0, formula C₃₂H₄₉N₉O₅·3HCl and molecular weight approximately 749.2 g/mol.

Where the supplied laboratory material contains hydrochloride, acetate, trifluoroacetate, residual water, solvents or formulation ingredients, the applicable batch documentation should identify their contribution to the total supplied material mass. The product specification should also state whether the nominal vial quantity represents parent SS-31 peptide equivalent or total supplied salt-form material.

Chromatographic purity should not automatically be interpreted as equivalent to total net SS-31 peptide content. Likewise, a bacterial endotoxin or lipopolysaccharide result does not establish sterility, molecular identity, correct stereochemistry, modified-residue identity, terminal amidation or the absence of every peptide-related and process-related impurity.

For the majority of routine analytical, chromatographic, peptide-characterisation and general laboratory work, the Regular SS-31 specification remains highly suitable. The premium black-and-gold ULTIMATE SS-31 option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet